Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVCN583601
- Development stage
- Unknown
- Lead developer
- Avicanna
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AVCN583601 is a topical cannabinoid-based pharmaceutical candidate developed by Avicanna for the treatment of Epidermolysis Bullosa (EB). EB is a group of rare genetic connective tissue disorders characterized by extremely fragile skin that blisters easily in response to minor friction or trauma. AVCN583601 is designed to address the significant unmet medical needs of EB patients, including chronic pain, inflammation, and impaired wound healing, by utilizing the therapeutic potential of cannabinoids. The program has undergone evaluation in Real-World Evidence (RWE) settings and is advancing into Phase 2/3 clinical trials.
Beyond the preview
Go deeper on AVCN583601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVCN583601.